Advertisement

Endocrine

, Volume 33, Issue 1, pp 101–105 | Cite as

Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones

  • Ozen OzEmail author
  • Ercan Tuncel
  • Salih Eryilmaz
  • Murat Fazlioglu
  • Cuma Bulent Gul
  • Canan Ersoy
  • Nihal Ocak
  • Melahat Dirican
  • Sengul Cangur
  • Ibrahim Baran
  • Sazi Imamoglu
Original Paper

Abstract

Background Thiazolidinediones (TZDs) improve peripheral insulin sensitivity, but the effect on arterial stiffness is less clear. The aim of the present study was to assess the differential effect of pioglitazone or rosiglitazone on arterial stiffness and plasma levels of adiponectin and leptin in patients with type 2 diabetes mellitus. Methods Thirty-five type 2 diabetic subjects were randomly assigned to receive pioglitazone (30 mg/day; n = 14), rosiglitazone (4 mg/day; n = 11), or placebo (medical nutrition therapy; n = 10) for 12 weeks. Changes in plasma glucose, glycosylated hemoglobin, insulin resistance (HOMA-IR), total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, adiponectin, and leptin were evaluated at baseline and after 12 weeks. In parallel, large arterial compliance (C1) and small arterial compliance (C2) were measured at baseline and at the end of treatment period. Results At 12 weeks, the rosiglitazone (P = 0.026) and pioglitazone (P = 0.004) groups had a significant increase from baseline in adiponectin that was not seen in the medical nutrition therapy group. No significant changes in plasma leptin and in C1 and C2 elasticity indexes were observed over the entire study period in any of the treatment groups. Conclusions In this study of patients with type 2 diabetes, treatment with TZDs was associated with a significant improvement in adiponectin levels, although no significant effects were seen on leptin levels and arterial elasticity.

Keywords

Thiazolidinediones Diabetes mellitus type 2 Adipokines Arterial elasticity 

References

  1. 1.
    R.S. Ahima, Adipose tissue as an endocrine organ. Obesity (Silver Spring) 14, 242S–249S (2006)CrossRefGoogle Scholar
  2. 2.
    M. Guerre-Millo, Adipose tissue and adipokines: for better or worse. Diabetes Metab. 30, 13–19 (2004)CrossRefPubMedGoogle Scholar
  3. 3.
    Y. Marcus, N. Stern, Fat cell-derived modulators of vascular cell pathophysiology: the list keeps growing. J. Cardiometab. Syndr. 1, 121–124 (2006)CrossRefPubMedGoogle Scholar
  4. 4.
    A.H. Berg, P.E. Scherer, Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96, 939–949 (2005)CrossRefPubMedGoogle Scholar
  5. 5.
    A. Singhal, I.S. Farooqi, T.J. Cole, et al., Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 106, 1919–1924 (2002)CrossRefPubMedGoogle Scholar
  6. 6.
    A. Mahmud, J. Feely, Adiponectin and arterial stiffness. Am. J. Hypertens. 18, 1543–1548 (2005)CrossRefPubMedGoogle Scholar
  7. 7.
    S. Zoungas, R.P. Asmar, Arterial stiffness and cardiovascular outcome. Clin. Exp. Pharmacol. Physiol. 34, 647–651 (2007)CrossRefPubMedGoogle Scholar
  8. 8.
    D.A. Duprez, J.N. Cohn, Arterial stiffness as a risk factor for coronary atherosclerosis. Curr. Atheroscler. Rep. 9, 139–144 (2007)CrossRefPubMedGoogle Scholar
  9. 9.
    C.B. Patel, J.A. De Lemos, K.L. Wyne, D.K. McGuire, Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism. Diab. Vasc. Dis. Res. 3, 65–71 (2006)CrossRefPubMedGoogle Scholar
  10. 10.
    C.M. Halabi, C.D. Sigmund, Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis: mechanisms and clinical implications. Am. J. Cardiovasc. Drugs 5, 389–398 (2005)CrossRefPubMedGoogle Scholar
  11. 11.
    R. Ríos-Vázquez, R. Marzoa-Rivas, I. Gil-Ortega, J.C. Kaski, Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am. J. Cardiovasc. Drugs 6, 231–242 (2006)CrossRefPubMedGoogle Scholar
  12. 12.
    B.K. Irons, R.S. Greene, T.A. Mazzolini, K.L. Edwards, R.B. Sleeper, Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy 26, 168–181 (2006)CrossRefPubMedGoogle Scholar
  13. 13.
    K. Shimada, T. Miyazaki, H. Daida, Adiponectin and atherosclerotic disease. Clin. Chim. Acta 344, 1–12 (2004)CrossRefPubMedGoogle Scholar
  14. 14.
    S.H. Han, M.J. Quon, K.K. Koh, Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 46, 1086–1092 (2005)CrossRefPubMedGoogle Scholar
  15. 15.
    P.J. Boyle, What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance? Clin. Cardiol. 27, IV11–IV16 (2004)CrossRefPubMedGoogle Scholar
  16. 16.
    Y. Sharabi, M. Oron-Herman, Y. Kamari, Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model. Am. J. Hypertens. 20, 206–210 (2007)CrossRefPubMedGoogle Scholar
  17. 17.
    M.L. Correia, K. Rahmouni, Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes. Metab. 8, 603–610 (2006)CrossRefPubMedGoogle Scholar
  18. 18.
    G. Derosa, A.F. Cicero, A. D’Angelo, et al., Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens. Res. 29, 849–856 (2006)CrossRefPubMedGoogle Scholar
  19. 19.
    H. Shimizu, S. Oh-I, T. Tsuchiya, K.I. Ohtani, S. Okada, M. Mori, Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study. Diabet. Med. 23, 253–257 (2006)CrossRefPubMedGoogle Scholar
  20. 20.
    S.G. Kim, O.H. Ryu, H.Y. Kim, et al., Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Eur. J. Endocrinol. 154, 433–440 (2006)CrossRefPubMedGoogle Scholar
  21. 21.
    J. Yu, N. Jin, G. Wang, F. Zhang, J. Mao, X. Wang, Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 56, 1396–1401 (2007)CrossRefPubMedGoogle Scholar
  22. 22.
    M.S. Goligorsky, Clinical assessment of endothelial dysfunction: combine and rule. Curr. Opin. Nephrol. Hypertens. 15, 617–624 (2006)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Ozen Oz
    • 1
    Email author
  • Ercan Tuncel
    • 2
  • Salih Eryilmaz
    • 3
  • Murat Fazlioglu
    • 3
  • Cuma Bulent Gul
    • 1
  • Canan Ersoy
    • 2
  • Nihal Ocak
    • 4
  • Melahat Dirican
    • 4
  • Sengul Cangur
    • 5
  • Ibrahim Baran
    • 3
  • Sazi Imamoglu
    • 2
  1. 1.Department of Internal MedicineUludag University Medical SchoolGorukle, BursaTurkey
  2. 2.Department of Endocrinology and MetabolismUludag University Medical SchoolBursaTurkey
  3. 3.Department of CardiologyUludag University Medical SchoolBursaTurkey
  4. 4.Department of BiochemistryUludag University Medical SchoolBursaTurkey
  5. 5.Department of StatisticsUludag University Medical SchoolBursaTurkey

Personalised recommendations